Scott S. Tykodi, MD, PhD
Department of Medicine
Division of Oncology
Seattle Cancer Care Alliance
825 Eastlake Ave E, G4810
Seattle, WA 98109
Specialty / Expertise
Melanoma and Kidney Cancer
The clinical application and translational study of natural or induced T cell immunity targeting renal cell carcinoma and other cancers.
Current Research Projects
Funded by: Pfizer, Inc.
A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Inhibitor In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Funded by: Immatics Biotechnologies GmbH
A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma
Funded by: GlaxoSmithKline
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy.
Funded by: Bristol-Myers Squibb
A Phase 1, Open-label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
Funded by: Novartis
A phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)
Dr. Tykodi received his MD and PhD from Washington University, St. Louis, MO. He completed his Internal Medicine Residency at the Barnes-Jewish Hospital, Washington University, St. Louis, MO. He was a Post-Doctoral Fellow in Medical Oncology at University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA.
Tykodi, S.S., Satoh, S., Deming, J. D., Chou, J., Harrop, R., and Warren, E. H. CD8+ T Cell Clones Specific for the 5T4 Antigen Target Renal Cell Carcinoma Tumor-Initiating Cells in a Murine Xenograft Model. J Immunother. 2012. 35:523-33.
Brahmer, J. R., Tykodi, S.S., Chow, L.Q.M., Hwu, W., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. S., Alaparthy, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D.M., Gupta, A., and Wigginton, J. M. Safety and Activity of Anti-PD-L1 (BMS-936559) in Patients with Advanced Solid Tumors. N Engl J Med. 2012 366:2455-65.
Tykodi, S. S., Sandmaier, B. M., Warren, E. H., and Thompson, J. A. Allogeneic Hematopoietic Cell Transplantation for Renal Cell Carcinoma: Ten Years After. Expert Opin. Biol. Ther. 2011. 11(6):763-73.
Tykodi S. S., Voong, L. N. and Warren, E. H. Combining Allogeneic Immunotherapy with an mTOR Inhibitor for Advanced Renal Cell Carcinoma. BMT. 2010. 45:1360-1362.
Bhatia, S., Tykodi, S. S., and Thompson, J. A.. Treatment of Metastatic Melanoma: An Overview. Oncology. 2009. 23:488-496.
Tykodi, S. S., Thompson, J. A. Development of Modified Vaccinia Ankara-5T4 as Specific Immunotherapy for Advanced Human Cancer. Expert Opin. Biol. Ther. 2008. 8:1947-1953.
Tykodi, S. S., Fujii, N., Vigneron, N., Lu, S. M., Mito, J. K., Miranda, M. X., Chou, J., Voong, L. N., Thompson, J. A., Sandmaier, B. M., Cresswell, P., Van den Eynde, B., Riddell, S. R. and Warren, E. H. C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clin Cancer Res. 2008. 14:5260-5269.
Warren, E. H., N. J. Vigneron, M. A. Gavin, P. G. Coulie, V. Stroobant, A. Dalet, S. S. Tykodi, S. M. Xuereb, J. M. Mito, S. R. Riddell, and B. J. Van den Eynde. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science. 2006. 313:1444-1447.
Tykodi, S. S., E. H. Warren, J. A. Thompson, S. R. Riddell, R. W. Childs, B. E. Otterud, M. F. Leppert, R. Storb and B. M. Sandmaier. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 2004. 10:7799-7811
Warren, E. H., S. S. Tykodi, M. Murata, B. M. Sandmaier, R. Storb, E. Jaffee, R. Childs, J. A. Thompson, P. D. Greenberg, and S. R. Riddell. T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy. 2002. 4:441
Last updated: February 2013